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OBJECTIVE—Obesity causes insulin resistance, which has
been interpreted as reduced downstream insulin signaling. How-
ever, changes in access of insulin to sensitive tissues such as
skeletal muscle may also play a role. Insulin injected directly into
skeletal muscle diffuses rapidly through the interstitial space to
cause glucose uptake. When insulin resistance is induced by
exogenous lipid infusion, this interstitial diffusion process is
curtailed. Thus, the possibility exists that hyperlipidemia, such as
that seen during obesity, may inhibit insulin action to muscle
cells and exacerbate insulin resistance. Here we asked whether
interstitial insulin diffusion is reduced in physiological obesity
induced by a high-fat diet (HFD).
RESEARCH DESIGN AND METHODS—Dogs were fed a
regular diet (lean) or one supplemented with bacon grease for
9–12 weeks (HFD). Basal insulin (0.2 mU  min
1  kg
1) euglyce-
mic clamps were performed on fat-fed animals (n  6). During
clamps performed under anesthesia, ﬁve sequential doses of
insulin were injected into the vastus medialis of one hind limb
(INJ); the contralateral limb (NINJ) served as a control.
RESULTS—INJ lymph insulin showed an increase above NINJ
in lean animals, but no change in HFD-fed animals. Muscle
glucose uptake observed in lean animals did not occur in
HFD-fed animals.
CONCLUSIONS—Insulin resistance induced by HFD caused a
failure of intramuscularly injected insulin to diffuse through the
interstitial space and failure to cause glucose uptake, compared
with normal animals. High-fat feeding prevents the appearance of
injected insulin in the interstitial space, thus reducing binding to
skeletal muscle cells and glucose uptake. Diabetes 59:619–626,
2010
I
nsulin resistance is associated with a number of
diseases, including cardiovascular disease, hyper-
tension (1), cancer (2), and obesity (1,3), as well as
type 2 diabetes. Much research into insulin resis-
tance has focused on insulin signaling, suggesting that
target cell (e.g., skeletal muscle) response to insulin is the
primary defect. Most recently, mitochondrial dysfunction
(4,5) and intracellular fat accumulation (6) have been
proposed as primary causes of insulin resistance. Despite
these efforts, there is no deﬁnitive conclusion as to the
primary cause of cellular insulin resistance.
There are a number of loci where insulin action can be
altered, including the direct effect of inﬂammatory cyto-
kines to attenuate distribution of blood ﬂow and glucose
uptake (7), and direct effects of plasma free fatty acids
(FFAs) to impede insulin signaling in the cell (4) and/or
reduce capillary recruitment (8). To act, insulin must cross
the capillary endothelium, traverse the interstitial ﬂuid
compartment, and thence access and bind to insulin
receptors. A reduction in insulin’s ability to diffuse through
the interstitial space in lipid-induced insulin resistance (9)
suggests that access to sensitive tissues (such as skeletal
muscle) may be important in addition to cellular insulin
resistance. In insulin-resistant situations, it is therefore
important to examine whether insulin can access cells
prior to stimulating cell signaling.
A high-fat diet (HFD), which induces obesity and leads
to deposition of fat in tissues (10,11), does not always
increase basal FFAs in humans or canines (12,13); but
large elevations of FFAs can be observed at night in
canines (13) and humans (14). Given the uncertainty
regarding the effect of HFDs on FFA levels in the circula-
tion, it is not yet known whether the effects of lipid
infusion on insulin action can be extrapolated to explain
how an HFD per se would affect insulin action and the
ability of insulin to diffuse through skeletal muscle.
Previous studies in our laboratory have shown that
insulin injected directly into healthy muscle is dissemi-
nated throughout the interstitial space, where the hor-
mone accesses myocytes and stimulates glucose uptake
(15). In a model of insulin resistance where plasma FFAs
were raised by lipid infusion, injected insulin was surpris-
ingly not detected in the interstitial space (lymph) of
skeletal muscle, supporting absence of elevated interstitial
insulin. Under this condition there was little stimulation of
glucose disposal (9). This latter result suggests that high
plasma FFAs may prevent insulin’s access to skeletal
muscle, resulting in insulin resistance. It cannot be con-
cluded whether this is a direct effect of elevated plasma
FFAs, or of acute insulin resistance induced by lipid
infusion. Therefore, it was important to examine whether
lipid elevated physiologically by an HFD would similarly
limit insulin’s access to muscle cells. For example, in dogs
fed a control diet, insulin stimulates the extravascular
distribution of insulin without effects on vascular distribu-
tion volume (16), suggesting that insulin can increase its
own access to insulin-sensitive tissues. This effect was lost
after induction of insulin resistance by an HFD (17),
possibly due to an alteration in the diffusion of insulin
through the interstitial space. In the present report, we
examined whether insulin resistance induced by an HFD
would simulate lipid infusion studies in which injected
insulin was not detected in lymph. If so, this would
implicate insulin access to muscle cells as an important
factor in dietary fat–induced insulin resistance.
From the Department of Physiology and Biophysics, University of Southern
California, Los Angeles, California.
Corresponding author: Richard N. Bergman, rbergman@usc.edu.
Received 3 June 2009 and accepted 16 November 2009. Published ahead of
print at http://diabetes.diabetesjournals.org on 3 December 2009. DOI:
10.2337/db09-0839.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
diabetes.diabetesjournals.org DIABETES, VOL. 59, MARCH 2010 619RESEARCH DESIGN AND METHODS
Animals. One-year-old male mongrel dogs were housed in individual cages in
the University of Southern California Medical School Vivarium and were kept
under controlled conditions (12-h light/12-h dark). Animals had free access to
water, and were fed once per day from 9:00–10:00 A.M. with 825 g dry chow
(60% Prolab Canine 2000, 40% Laboratory High Density Canine Diet 5LI8; PMI
Nutrition International, Brentwood, MO) and one can of Purina Pro-Plan
Puppy Classic (Nestle Purina PetCare, St Louis, MO). For fat feeding, animals
were subjected to the basal diet, supplemented with 6 g/kg bacon grease,
presented to the dogs for the remainder of the study (15.2  0.8 weeks). We
have previously published data from injecting insulin into normal-weight dogs
(lean) fed ad lib dry chow (15); these previous results are reproduced with
permission herein for comparison and were not different when performed
before or after the HFD experiments. Dogs were used for experiments only if
they were judged to be in good health as determined by visual observation,
body weight, hematocrit, and body temperature. Protocols were approved by
the University of Southern California Institutional Animal Care and Use
Committee and were in accordance with the Principles of Laboratory Animal
Care.
Study design. Weekly fasted (basal) plasma samples for measurement of
FFAs were taken into tubes with 50 l EDTA and paraoxon to inhibit lipase
activity and centrifuged, and the plasma was frozen before analysis using a
colorimetric kit (NEFA-HR(2); Wako Diagnostics, Richmond, VA). Prior to
beginning the HFD, each animal (n  6) underwent magnetic resonance
imaging (MRI) of the abdominal area as outlined below, and a hyperinsuline-
mic euglycemic clamp (EGC) for determination of insulin sensitivity (SI) and
glucose turnover. Once these baseline parameters were established, the HFD
was administered, and the MRIs and EGCs were repeated (weeks 12–13).
Finally, an acute injection procedure was performed prior to death to
determine the local dynamics of injected insulin as detailed below. Lean
animals received the acute injection procedure, but did not receive MRIs or
EGCs.
MRI. On the morning of each MRI scan, a subcutaneous injection of
acepromazine (0.04 mg/kg; Bioceutical, St Joseph, MO) and atropine sulfate
(0.1 mg/kg, 1/120 grain; Western Medical, Arcadia, CA) was administered for
preanesthesia; dogs then received intravenous anesthesia of ketamine HCl (10
mg/kg; Phoenix Pharmaceutical, St Joseph, MO) and diazepam (0.2 mg/kg;
Abbott Laboratories, North Chicago, IL). Body composition was then assessed
in 30 1-cm axial abdominal images using 1.5 Tesla Horizon Magnet (version 5.7
software). Each MRI slice was analyzed using Scion Image Software (Win-
dows 2000 version Beta 4.0.2; Scion, Frederick, MD), which quantiﬁes fat
tissue (pixel values 121–254) and nonfat tissue (pixel values 20–120). The total
pixels of fat and nonfat tissue were used to calculate the area of fat located
within the peritoneal cavity in an 11-cm region of the thorax identiﬁed by the
central landmark slice, where the left renal artery branches from the abdom-
inal aorta. Subcutaneous fat volume was calculated as total fat in the
assessment region minus the visceral fat volume.
Hyperinsulinemic EGC studies. A primed infusion of [
3-H3]-D-glucose tracer
was started at t  120 min (25-Ci bolus  0.25 Ci/min; DuPont-NEN,
Boston, MA) into the saphenous vein in conscious animals. An infusion of
insulin (0.75 mU  min
1  kg
1; Lilly, Indianapolis, IN) and somatostatin (1.0
g  min
1  kg
1; Bachem California, Torrance, CA) was initiated at time 0,
and radiolabeled dextrose (2.0 Ci/g, [3-H
3]-D-glucose, 50% dextrose) was
variably infused to maintain euglycemia and speciﬁc activity. Blood samples
were drawn from the cephalic vein every 10 min from t  30 to 180 min.
Euglycemia was deﬁned as the average basal glucose and steady state as the
ﬁnal 30 min of the clamp. SI was calculated using the equation SI 
Ginf/(IxG), where Ginf  change in glucose infusion at steady state from
basal, I  change in plasma insulin at steady state from basal, and G 
steady-state plasma glucose concentration.
Acute insulin injection studies: surgery. These experiments were terminal
studies performed under anesthesia. Injection studies were performed on lean
animals and on animals given 15.2  0.8 weeks of HFD. Animals were fasted
15 h before the experiment, which began at 6:00 A.M. They were preanesthe-
tized with acepromazine maleate (Prom-Ace, 0.22 mg/kg; Aueco, Fort Dodge,
IA) and atropine sulfate (0.11 ml/kg; Western Medical). Anesthesia was
induced with sodium pentobarbital (0.44 ml/kg; Western Medical) and main-
tained with isoﬂurane (Western Medical). Dogs were placed on heating pads
to maintain body temperature. Indwelling catheters were inserted into the
right jugular vein for a continuous saline drip (1 l for the ﬁrst 60 min of
surgery and a slow drip thereafter) and into the left carotid artery for sampling
and blood pressure monitoring (model 90603A; Space Labs, Issaquah, WA).
Intracatheters were inserted into the left cephalic vein for variable glucose
infusion and the right cephalic vein for insulin and somatostatin infusion.
Indwelling catheters were also placed into both the right and left femoral
arteries and veins for blood sampling. Two perivascular ultrasonic ﬂowprobes
(2-mm diameter; Transonic, Ithaca, NY) were placed around both right and left
femoral arteries proximal to the femoral catheter. Left and right hind limb
lymphatic vessels were cannulated by placing polyethylene catheters (PE10)
into the afferent lymphatic vessels of the deep inguinal lymph node. Blood
pressure, heart rate, O2 saturation, and CO2 were monitored continuously. At
the conclusion of these experiments, animals were killed with an overdose of
sodium pentobarbital (Eutha-6, 65 mg/kg; Western Medical).
Blood glucose control during insulin injection. Immediately after starting
surgical procedures (t  180 min), simultaneous systemic infusions of
somatostatin (1 g  min
1  kg
1) and basal insulin replacement (0.2 mU 
min
1  kg
1) were begun and continued for the duration of the study (Fig. 1).
Exogenous 20% glucose was infused at variable rates to maintain euglycemia
at the basal level based on glucose measurements from the injected leg’s (INJ)
femoral artery plasma glucose (measured prior to insulin infusion) throughout
the entire experimental period (t  240 to 300 min). Samples were taken
simultaneously from the right and left femoral arteries and veins. Left and
right hind limb lymph vessels were sampled by gently massaging the hind limb
distal to the site of catheterization from 2 min prior to 2 min after each blood
sample.
Unilateral intramuscular insulin injection. As previously described (15),
at times 0, 60, 120, 180, and 240 min, porcine insulin (0.3, 0.5, 0.7, 1, and 3 U,
represented as I1, I2, I3, I4, and I5, respectively) was injected directly into the
vastus medialis of the quadriceps femoris of one leg. At each time point, two
30-gauge needles with a volume of 0.5 ml per syringe injected the appropriate
concentration of insulin at 0.6 ml/min. For individual experiments, either
right or left hind limb was chosen at random for injections (INJ) and the
noninjected contralateral limb (NINJ) was used for comparison. Plasma and
lymph samples were taken every 10 min after each injection.
Assays. Plasma and lymph samples were collected in microtubes that were
precoated with lithium-heparin (Becton Dickinson, Franklin Lakes, NJ) and
assayed for insulin and glucose. Arterial and venous tubes also contained 50
L EDTA (Sigma Chemicals). Blood samples were centrifuged immediately,
and the supernatant was transferred and stored at 20°C until further assay.
INJ femoral artery plasma samples were immediately assayed for glucose with
a YSI 2700 auto analyzer (Yellow Springs Instruments, Yellow Springs, OH)
before freezing at 20°C. Lymph samples were stored at 20°C after
sampling. Samples were assayed for insulin by ELISA (Linco Research)
adapted for canine plasma with a standard provided by Novo Nordisk, and for
glucose with a YSI 2700 auto analyzer.
Calculations. Glucose uptake across each limb was calculated based on the
Fick principle: LGU  (GA  GV)  BF, where LGU  local glucose uptake;
GA  arterial glucose; GV  venous glucose; and BF  femoral blood ﬂow.
Statistical analyses. All experimental data are expressed as the means 
SE. Statistical analyses were performed with unpaired Student t tests, or one-
or two-way ANOVAs with Tukey pairwise comparisons as appropriate. The
lean and HFD groups were compared using unpaired t tests and two-way
ANOVAs.
EUGLYCEMIC CLAMP
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FIG. 1. Euglycemic basal insulin clamp protocol. Time in minutes is
shown across the top. Somatostatin was infused with basal insulin
replacement; glucose was infused at a variable rate to maintain eugly-
cemia based on the INJ arterial glucose measurement. Samples were
taken at 15-min intervals from 60 to 0 min, and at 10-min intervals
from time 0–300 from the femoral artery, femoral vein, and lymph of
INJ and NINJ legs. I1, I2, I3, I4, and I5 represent insulin injections of
0.3, 0.5, 0.7, 1.0, and 3.0 units, respectively, which occurred every 60
min from time 0.
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Fourteen weeks of fat feeding caused an increase in body
weight, as shown in Fig. 2A, and also resulted in an
increase in both subcutaneous and abdominal fat, as
measured by MRIs shown in Fig. 2B. On average, fat-
fed dogs increased visceral fat by 79.4% (from 462.5  81.4
cm
3 to 803.2  154.3 cm
3, P  0.02) and subcutaneous fat
by 108.9% (from 902.2  183.1 cm
3 to 1952.3  502.1 cm
3,
P  0.03).
Basal-fasted plasma FFAs decreased with fat feeding
from 0.66  0.11 mmol/l to 0.40  0.07 mmol/l (P  0.02).
During the course of the experiment, the plasma FFA
levels dropped to levels virtually undetectable by the FFA
assay used (data not presented), as inhalant isoﬂurane
anesthesia is known to suppress lipolysis (18).
Systemic insulin action. As expected, HFD induced sig-
niﬁcant peripheral insulin resistance determined by the
hyperinsulinemic euglycemic clamp in conscious dogs (week
0: 8.72  0.27 to week 12: 3.15  0.65 dl  pM
1  mg
1 
kg
1, P  0.02) (Fig. 3A). Glucose disposal (Rd) decreased
from 11.49  1.53 mg  min
1  kg
1 prior to fat feeding to
7.26  1.55 mg  min
1  kg
1 after 12 weeks of HFD (P 
0.03) (Fig. 3B). Endogenous glucose production showed a
trend to increase (week 0: 0.18  0.27 to week 12: 0.69 
0.41 mg  min
1  kg
1, P  0.36) (Fig. 3C). HFD caused the
dogs to become insulin resistant, and this was more
evident in the periphery than in the liver.
Local insulin action: lean animals. As previously re-
ported, insulin injections caused a small increase in both
INJ and NINJ femoral artery insulin over the course of the
experiment (INJ: 0 min, 11.9  1.0; 300 min, 35.9  1.9
mU/l, P 	 0.001. NINJ: 0 min, 12.4  1.2; 300 min, 36.6 
2.5 mU/l, P 	 0.001) (Fig. 4A). Femoral vein insulin was
signiﬁcantly increased after the ﬁnal injection in INJ
compared with NINJ (300 min: NINJ, 35.8  2.0; INJ,
64.0  10.5 mU/l, P  0.02) (Fig. 4B), demonstrating a
washout of insulin injected into the muscle that then
entered the systemic circulation to cause the small eleva-
tions in arterial insulin. INJ lymph insulin concentrations
increased after the second injection compared with NINJ
and remained signiﬁcantly elevated until the end of the
experiment (300 min: NINJ, 13.2  2.3; INJ, 73.8  7.1
mU/l, P 	 0.01) (Fig. 4C). The concentration of insulin in
the interstitial ﬂuid of NINJ remained approximately half
of that of the arterial insulin supply. Insulin injection into
muscle induced an increase in glucose infusion required to
maintain euglycemia in lean animals, as well as a signiﬁ-
cant increase in local glucose uptake in the injected limb
(300 min: NINJ, 9.5  4.5; INJ, 27.3  4.0 mg  min
1  kg
1,
P  0.03) (Fig. 5A).
Local insulin action: fat-fed animals. In HFD-fed ani-
mals, in sharp contrast to lean animals, INJ lymph insulin
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during injection into the muscle compared with the con-
tralateral noninjected limb (300 min: NINJ, 20.9  1.4; INJ,
26.6  4.9 mU/l, P  0.232) (Fig. 4C). The minor increase
in femoral artery insulin over time was observed similar to
lean animals and not different between legs (INJ: 0 min,
15.7  1.1; 300 min, 47.6  2.4 mU/l, P 	 0.001. NINJ: 0
min, 17.3  1.4; 300 min, 46.8  3.2 mU/l, P 	 0.001) (Fig.
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FIG. 4. Insulin concentration in femoral artery (A), femoral vein (B), and lymph (C). Lean animals are included (left column) compared with new
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compared with NINJ (300 min: HFD NINJ, 49.6  5.55;
HFD INJ, 133.9  22.9 mU/l, P  0.03) and lean INJ (300
min: HFD INJ, 133.9  22.9; lean INJ, 64.0  10.5 mU/l, P 
0.01), reﬂecting a signiﬁcantly greater washout of insulin
from the injected area in HFD-fed compared with lean
animals from 210 min to the end of the experiment (Fig.
4B). The interstitial ﬂuid insulin concentration in NINJ
was approximately half the arterial insulin concentration;
this was not signiﬁcantly different compared with lean
animals and did not change throughout the experiment.
The glucose infusion for fat-fed animals was not signiﬁ-
cantly different from lean animals, however the femoral
artery glucose was signiﬁcantly higher than in the lean
animals due to a higher basal glucose measured prior to
insulin and somatostatin infusion (lean: 96.0  2.1; HFD:
11.6  4.8 mg/dl, P  0.01, unpaired t test). There was
no signiﬁcant glucose uptake due to insulin injection
(300 min: INJ 5.9  7.14; NINJ 4.68  6.2 mg  min
1  leg
1,
P  0.328), which was signiﬁcantly lower than in lean
animals (P  0.02) (Fig. 5). There was no signiﬁcant
difference in blood ﬂow (Fig. 6), mean arterial pressure
(lean: 63.82  3.01; HFD: 68.83  3.56 mmHg), or heart
rate (lean: 110.09  4.79; HFD: 111.67  5.72 bpm)
between groups.
DISCUSSION
Physiological insulin resistance induced by feeding an
HFD for 14 weeks caused a failure of insulin injected into
skeletal muscle to be detected in lymph and prevented
glucose uptake in response to the injection compared with
lean animals. This is reminiscent of previously published
results that show experimentally elevated plasma lipids
likewise inhibit the ability of injected insulin to diffuse
through muscle and initiate glucose uptake (9). Interest-
ingly, the ability of the HFD to impair insulin dispersion in
muscle occurs in the absence of a rise in plasma FFAs,
either under basal-fasting conditions or during the clamp.
There was no signiﬁcant difference between the injected
and noninjected arterial insulin in the fat-fed animals, as
the arterial supply to both legs should be the same and the
insulin injection occurs distal to the arterial sampling
point. Also, there is no signiﬁcant difference between the
femoral artery and vein insulin concentrations of the
noninjected leg, so the increase observed in the femoral
vein insulin concentration of the injected leg was due to
insulin overﬂow from the local area of the injection.
Among the high-fat–fed animals, there was variation in the
ability of lymph to reﬂect the more concentrated insulin
injections. As the ratio of NINJ lymph to arterial insulin
was maintained in the face of increasing systemic insulin,
the ability of lymph to detect whole-body insulin changes
was not altered.
Lymph measures of interstitial insulin have previously
been used in this laboratory (9,15–17,19,20) and others
(21–24), and agree with other measures of interstitial
insulin such as microdialysis (25). Further, gold injected
into the interstitium has been shown to concentrate in
lymph vessels (26). Due to the low ﬂow rate and apparent
lack of size exclusion of lymph vessels, rapid equilibration
of lymph with the intracellular ﬂuid can occur similar to
that used in microdialysis, and as such is an appropriate
tool for measuring interstitial insulin concentrations, re-
ﬂecting the makeup of the interstitial ﬂuid to which
myocytes are exposed. One limitation in our study is that
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the entire leg, whereas insulin is injected into a small area
of one muscle; thus the interstitial concentration of insulin
in the injected area may be higher than in lymph due to
dilution of lymph from uninjected muscle. However, pre-
vious results have shown a signiﬁcant increase in lymph
insulin in lean dogs (15), thus HFD has impaired the
appearance of insulin in lymph.
We show that the ability of insulin to access myocytes is
impaired in physiological insulin resistance, and several
proposed causes of insulin resistance are unable to de-
scribe the results we observe here. For example, mito-
chondrial dysfunction has been proposed as a critical
component of insulin resistance (27), yet in our study,
cells are not exposed to elevated insulin, and as such,
mitochondrial dysfunction is unlikely to be responsible for
the impaired dispersion of insulin. Studies in obese mice
have shown that mitochondrial dysfunction is evident in
adipose tissue, but not in skeletal muscle (28), and al-
though stimulating FFA oxidation in skeletal muscle re-
duces insulin resistance (29), it does not necessarily
follow that mitochondrial function is the primary cause of
skeletal muscle insulin resistance. Similarly, it is unlikely
that downstream signaling impairment in myocytes (30,31)
or intracellular fat accumulation (6,32) impaired glucose
uptake in our study, as there was apparently no measur-
able elevation of interstitial insulin to cause insulin’s
cellular effects. However, we cannot discount that myo-
cytes would exhibit insulin resistance if the cells were
actually exposed to injected insulin in our model.
The mechanism(s) by which HFD prevents injected
insulin from appearing in the interstitial space cannot be
clariﬁed from the experiments presented here. As acute
hyperlipidemia also resulted in reduced insulin appear-
ance in the interstitial ﬂuid (9), it is unlikely to be a
structural change. One possibility is a lipid-induced alter-
ation in permeability of the endothelial cell (33,34), which
might allow a more rapid egress of insulin from the
interstitial compartment into the bloodstream. However,
this permeability theory does not identify the location of
the injected insulin prior to appearance in the vein, which
may occur as much as 1 h later. It was noted that, although
insulin was not detected in lymph, venous insulin had not
dropped to preinjection levels even 1 h after injection. As
less than 30% of the injected insulin is removed by the vein
during the course of the experiment, the remainder must
in theory be contained within the muscle, although is not
detected in the interstitial space. The excess may be taken
up into some cells. Insulin is internalized by endothelial
cells en route to the vein (35), and, as endothelial cells
exhibit insulin resistance (36), this internalization may be
increased in obesity to overcome the impaired insulin
signaling, thus removing insulin from the interstitial space.
As there is no insulin in the interstitial space, only myo-
cytes immediately adjacent to the area of injection may
internalize insulin. Alternatively, in lean animals, injected
insulin could increase the perfusion of muscle and aug-
ment the blood ﬂow to the area, therefore increasing the
dispersion of insulin through the muscle (37). Obese rats
(38) and those with pharmacologically elevated lipids (8)
have impaired insulin-mediated capillary recruitment; in-
sulin injected into the muscle may be trapped in the small
area of injection, without the means to increase its disper-
sion area. It is also possible that the local high insulin
concentration after injection is in the interstitial space,
although not in an area sampled by the lymph. In lean
animals, injected insulin would cause an increase in the
distribution volume to allow more complete dissemination
of insulin through the muscle, and therefore detection in
the lymph. Adiposity would prevent this increase in distribu-
tion volume (39) and reduce the appearance of insulin in the
lymph, as less of the muscle is exposed to insulin.
The role of the endothelial cell in the transport of insulin
is unclear—evidence exists for both paracellular and
transcellular transport of insulin. A recent study has
shown that in cell culture, endothelial cells concentrate
insulin (38); whether this occurs in vivo has not been
determined, and there is no indication of whether this is
unidirectional or can move from plasma to interstitium
and back. As lean animals show signiﬁcant insulin appear-
ance in the vein, insulin can move in both directions.
Although endothelial cells exhibit insulin resistance (36),
effects on insulin transport are not known; however,
insulin resistance can impair the appearance of insulin in
the interstitium (20,23), and transport is known to be rate
limiting to insulin action (19,20,22).
Although we have shown that insulin resistance, either
chronic (HFD) or acute (9), prevents dissemination of
insulin through the muscle, the mechanism is not yet
known. As the HFD does not increase, and in fact sup-
presses basal plasma FFAs, and isoﬂurane anesthesia
reduces plasma FFAs by 70% (17), plasma FFAs are
unlikely to be the primary cause of the impaired dissemi-
nation of injected insulin. However, as plasma lipids are
elevated nocturnally by an HFD (13), it is possible that
whereas plasma FFAs are not a direct cause of insulin
resistance in our study, tissue FFA levels may be. In-
tramyocellular lipid content can be altered by diet (11) and
acutely by lipid infusion (40); as many cells are not
exposed to injected insulin, it is unlikely that the intracel-
lular lipid would affect our results, although there is the
possibility of extracellular fat accumulation. It is unclear
whether lipids must be in the interstitial space to inhibit
dispersion of intramuscularly injected insulin, or whether
another factor may be inhibiting the dispersion of insulin.
The HFD dogs were subjected to a signiﬁcantly higher
glucose level than the lean animals throughout the injec-
tion procedure, as their plasma glucose level after anes-
thesia and prior to insulin and somatostatin infusion was
higher. The arterial glucose of animals infused with lipid is
not signiﬁcantly different from either lean or HFD-fed
animals, and values appear to be intermediate (9). Endo-
thelial dysfunction may be caused by both acute hypergly-
cemia (41) and hyperlipidemia (42), which may prevent
insulin-induced capillary recruitment. Thus, impaired in-
sulin dispersion observed with lipid infusion (9) and fat
feeding may result from different plasma factors that
ultimately affect the capillary endothelium. Further studies
are necessary to determine whether elevated glucose
affects the dispersion of injected insulin.
In conclusion, in an HFD, which induces chronic insulin
resistance, insulin injected directly into the muscle is not
detectable in the interstitial space (lymph), but appears to
wash out in the venous blood ﬂow. This is similar to
previous results (9) that demonstrate acute lipid-induced
insulin resistance prevented injected insulin from diffusing
through the interstitium. The apparent cellular insulin
resistance occurs because myocytes are not exposed to
insulin; potential downstream effectors such as mitochon-
drial dysfunction, intramyocellular fat accumulation, and
signaling impairment are unlikely to be responsible for the
inability of injected insulin to diffuse through the intersti-
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the injection study is not a physiological situation, there
are clear differences in how insulin is dealt with in the
interstitium, and its access to muscle. Therefore, studies
on the insulin sensitivity of individual cells should con-
sider whether insulin was able to access the tissue prior to
any perceived defect in insulin signaling or response.
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